App-Quantinova.ai

Pathology of Hypo-Attenuated Leaflet Thickening (HALT) in CoreValve/Evolut Self-expanding Transcatheter Aortic Valve Bioprostheses

Yu Sato - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

Low-Dose or Standard-Dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Mijin Kim - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Edoxaban

Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

Yeonwoo Choi - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

The Importance of Leaflet Design in Initiation and Growth of Leaflet Thrombosis in Transcatheter Aortic Valves

Dong Qiu - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

On the Likelihood of Leaflet Thrombosis Following Transcatheter Pulmonary Valve Replacement

Mina Shafiei - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Predicting Device-Related Thrombosis Using Computational Fluid Dynamics

Brennan Vogl - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Low-Molecular-Weight Heparin as Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Gastrointestinal Bleeding

Xavier Millan - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Heparin

Long-Term 10 Years’ Follow-Up for Valve Dysfunction and Mean Gradient Change in Transcatheter Aortic Valve Replacement (TAVR)

Abdulaziz Algethami - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Sex Differences in Ticagrelor With or Without Aspirin After Percutaneous Coronary Interventions in Acute Coronary Syndrome Patients: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial

Jong-Il Park - Transcatheter Cardiovascular Therapeutics (TCT) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Ticagrelor

Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention

Nadir Elamin - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Heparin

Fully automated quantitative stress perfusion cardiac mri to assess myocardial perfusion in adult patients with convalescent kawasaki disease and coronary aneurysms: an age and sex-matched analysis

Kevin Cheng - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Pim kinase is a novel regulator of endothelium-driven thrombosis.

Eima Karim - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

AZD-1208

SIRT1: a novel regulator of integrin αiibβ3 and actin cytoskeleton dynamics in platelets

Maria Blanco - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Fibrinogen (IV)

Characterising variations in the composition of native extracellular matrix in a model of arterial thrombosis

Amelia Drysdale - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Exploratory Analysis of Filgotinib Safety Data in Patients With Moderately to Severely Active Rheumatoid arthritis and an Increased Risk of Cardiovascular Events: Data From Phase 2 and 3 Clinical Trials

Maya H Buch - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Filgotinib

The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in Rheumatoid Arthritis

Patrick Durez - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Filgotinib

Intracardiac thrombosis and vascular involvement in Behçet's disease: two sides of the same coin?

Sarra Chadli - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Uniqueness of venous thrombosis in Behçet's syndrome: a case series of 62 patients

Sarra Chadli - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Catheter-related venous thrombosis in patients with systemic sclerosis: a case series

Chiara Giacomassi - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial

Kerry Reynolds - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Methylprednisolone

Filters

7277 Abstracts